Similar to work by Mattarollo [31], in which they transplanted primary B-cell lymphomas derived from Eμ-myc transgenic mice into immunocompetent recipients and treated by vaccination with α-GalCer–loaded autologous tumor cells, we found that the activation of NKT cells resulted in significant inhibition of tumor growth and was associated with high levels of IFN-γ. The gene discussed is IFNG; the disease is B-cell non-Hodgkin lymphoma.